secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0000950170-24-113404
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M
------------------------------------------------------------------

- Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.
- Cash and equivalents $4.9M as of June 30, 2024.
- FY2024 net loss $8.3M ($0.32 loss per share), improved from $14.6M ($9.27 loss) in FY2023.
- REM-001 study dosed 4 patients; $2.0M NIH grant covers most costs; R&D expenses fell 71%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/0000950170-24-113404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/ktra-20241007.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer